
Supplement Figure Legend



Supplement Figure 1 The diagnosis of the autoimmune pancreatitis patients following the international consensus diagnostic criteria. *The histopathological diagnosis results were graded as: LPSP Level 1, LPSP Level 2, and "rule out malignant tumor". Some of the non-diagnostic cases chose to take the diagnostic steroid trial, while the others chose to receive the EUS-FNA; other than LPSP level 1 pathological finding, cases who received FNA will also take the diagnostic steroid trial. The response to steroid therapy was evaluated after two weeks with dynamic computed tomography or magnetic resonance. Cases who got the level 1 LPSP pathological findings and who responded to the diagnostic steroid trial would be finally diagnosed with AIP following the criteria of ICDC. In our center, we didn't routinely do endoscopic retrograde pancreatography in all AIP patients for the risk of post ERCP pancreatitis. AIP: Autoimmune pancreatitis; EUS: Endoscopic ultrasound; FNA: Fine-needle aspiration; ICDC: International consensus diagnostic criteria; LPSP: Lymphoplasmacytic sclerosing pancreatitis.

Supplement Table Legend

Supplement Table 1 Definitions of endoscopic ultrasound findings in autoimmune pancreatitis

EUS findings	Definitions	Histological correlate
Parenchymal changes		
DHA or FHA ¹	Pancreatic parenchyma displays lower	Inflammation of
	echogenicity than the renal cortex	lymphoplasmacytic
		infiltrates
Calcification ²	Hyperechoic lesion with acoustic shadowing	Parenchymal
	within the pancreas	calcification
Lobularity	Well-circumscribed, \geq 5 mm structures with	Fibrosis, glandular
	enhancing rim and relatively echo-poor center	atrophy
With honeycombing ²	Contiguous ≥ 3 lobules	
Without honeycombing ³		
HF^{3}	Echogenic structures foci \ge 2 mm in both	Focal fibrosis
	length and width with no shadowing	
HS^{3}	Hyperechoic lines of \geq 3 mm in length in at	Bridging fibrosis
	least 2 different directions with respect to the	
	imaged plane	
Cystic lesion ³	Anechoic, rounded/elliptical structures with	Pseudocyst
	or without septa	
Main pancreatic duct changes		
MPD calculi ²	Echogenic structure(s) within MPD with	Stones
	acoustic shadowing	
Diffuse stenosis/irregularity	Diffuse uneven or irregular outline and ectatic	Unknown
	course	
MPD dilation ³	> 3 mm in the head, > 2 mm in the body, > 1	
	mm in the tail	

Hyperechoic duct margin ³	Hyperechoic margins of the MPD	Periductal fibrosis	
Bile duct involvement			
Bile duct wall thickening	The hypoechoic layer on the internal aspect of	IgG4 associated	
	the bile duct is clearly thickened > 1 mm, either	cholangitis	
	with a symmetric 3-layer type or a		
	parenchymal-echo type		
Intrapancreatic bile stenosis	The lumen diameter of intrapancreatic part of		
	common bile duct less than 1 mm		
Peripancreatic changes			
Peripancreatic	Lymph node longest diameter ≥ 10 mm		
lymphadenopathy			
Peripancreatic hypoechoic	A capsule-like hypoechoic rim defined in the	Unknown	
margin	EUS		
Lobular outer margin	The lobular appearance of the pancreatic edge	Unknown	
Peripancreatic vessel	Obstruction/stricture/thrombosis of		
involvement	splenic/portal vein		

¹DHA: the pancreas is divided into three parts: head, body, and tail; diffuse hypoechoic area means more than one part of pancreas is involved under EUS; FHA, less than one part involved. ²Included as major criteria in the Rosemont criteria.³Included as minor criteria in the Rosemont criteria. AIP: Autoimmune pancreatitis; DHA: Diffuse hypoechoic area; EUS: Endoscopic ultrasound; FHA: Focal hypoechoic area; FS: Focal stenosis; HF: Hyperechoic foci; HS: Hyperechoic strand; MPD: Main pancreatic duct; mm, millimeter. Supplement Table 2 Comparison of endoscopic ultrasound features between focal autoimmune pancreatitis cases with or without head involvement

	Focal type	Head involved	Non-head	head	
EUS findings		(n = 50)	involved ($n =$	P value	
	(n = 71)		21)		
Typical findings					
DHA	16 (22.5)	12 (24.0)	4 (19.0)	0.76^{1}	
FHA	59 (83.1)	41 (82.0)	18 (85.7)	1.00^{1}	
Bile duct changes					
Bile duct wall thickening	37 (52.1)	33 (66.0)	4 (19.0)	< 0.001	
Intrapancreatic bile duct	24(47.0)	20 (59 0)	E (72.8)	0.01	
stenosis	34 (47.9)	29 (58.0)	5 (23.8)	0.01	
Extrahepatic bile duct dilation	25 (35.2)	22 (44.0)	3 (14.3)	0.02	
Peripancreatic changes					
Peripancreatic	17 (23.9)	14 (28.0)	3 (14.3)	0.22	
lymphadenopathy	17 (23.9)	14 (20.0)	5 (14.5)	0.22	
Peripancreatic hypoechoic	5 (7 0)	2(60)	2(0.5)	0.63 ¹	
margin	5 (7.0)	3 (6.0)	2 (9.5)	0.03*	
Lobular outer margin	6 (8.5)	5 (10.0)	1 (4.8)	0.661	
Peripancreatic vessel	5 (7 0)	2(60)	2(0.5)	0.621	
involvement	5 (7.0)	3 (6.0)	2 (9.5)	0.631	
Chronic pancreatitis changes					
Parenchymal changes					
HF	69 (97.2)	48 (96.0)	21 (100.0)	1.00^{1}	
HS	43 (60.6)	33 (66.0)	10 (47.6)	0.15	
Cystic lesion	4 (5.6)	1 (2.0)	3 (14.3)	0.08^{1}	
Parenchymal calcification	1 (1.4)	0 (0)	1 (4.8)	0.301	

Lobularity with honeycombing		7 (9.9)	5 (10.0)	2 (9.5)	1.001
Lobularity	without	12(1(0))	0 (19 0)	2(14.2)	1 001
honeycombing		12 (16.9)	9 (18.0)	3 (14.3)	1.00^{1}
Main pancreatic duct c					
MPD calculi		1 (1.4)	0 (0)	1 (4.8)	0.30 ¹
MPD dilation		18 (25.3)	16 (32.0)	2 (9.5)	0.05
Diffuse stenosis/irregularity		9 (12.7)	9 (18.0)	0 (0)	0.05
Focal stenosis		5 (7.0)	5 (10.0)	0 (0)	0.31
Hyperechoic duct ma	rgin	28 (39.4)	20 (40.0)	8 (38.1)	0.88

¹Fisher's exact test. Results presented as n (%). AIP: Autoimmune pancreatitis; DHA: Diffuse hypoechoic area; EUS: Endoscopic ultrasound; FHA: Focal hypoechoic area; HF: Hyperechoic foci; HS: Hyperechoic strand; MPD: Main pancreatic duct.

	Farrell <i>et al</i> ^[10] ($n =$	Hoki <i>et al</i> ^[11] (n	Okabe <i>et al</i> ^[12] (<i>n</i>	Our study $(n =$	
EUS findings	14)	= 25)	= 32)	285)	
Diffuse type	8 (57)	15 (60)	21 (65.6)	214(75.8)	
Focal type	6 (43)	10 (40)	11 (34.3)	71 (33.2)	
Typical findings					
DHA	8 (57)	22 (88)	NA	213 (74.7)	
FHA	6 (43)	11 (44)	NA	59 (20.7)	
Bile duct changes					
Bile duct wall thickening	NA	9/17 (53) ¹	NA	195 (68.4)	
Intrapancreatic bile duct stenosis	NA	NA	NA	165 (57.9)	
Extrahepatic bile duct dilation	NA	NA	NA	122 (42.8)	
Peripancreatic char	nges				
Peripancreatic lymphadenopathy	6 (43)	18 (72)	NA	89 (31.2)	
Peripancreatic hypoechoic margin	NA	5 (20)	NA	81 (28.4)	
Lobular outer margin	NA	NA	20 (62.5)	40 (14.0)	
Peripancreatic vessel involvement	3 (21.4)	NA	NA	21 (7.4)	
Chronic pancreatitis changes					
Parenchymal chang	ges				
HF	NA	8 (32)	32 (100)	271 (95.1)	

Supplement Table 3 The systematic review of endoscopic ultrasound features of autoimmune pancreatitis

HS	NA	14 (56)	26 (81.3)	174 (61.1)
Cystic lesion	1 (7.1)	4 (16)	NA	18 (6.3)
Parenchymal	NT A	A (1C)	NT A	2(1,1)
calcification	NA	4 (16)	NA	3 (1.1)
Lobularity with	NT A	NT A	NT A	2(0,1)
honeycombing	NA	NA	NA	26 (9.1)
Lobularity				
without	1 (7.1)	2 (8)	17 (53.1)	48 (16.8)
honeycombing				
Main pancreatic du	uct changes			
MPD calculi	NA	NA	NA	1 (0.4)
MPD dilation	NA	3 (12)	NA	48 (16.8)
Diffuse	NT A	10 (40)	NT A	20(10.2)
stenosis/irregularity	NA	10 (40)	NA	29 (10.2)
Focal stenosis	NA	NA	NA	11 (3.9)
Hyperechoic	NTA	0 (26)	NT A	110 (11 0)
duct margin	NA	9 (36)	NA	119 (41.8)

¹Excluding patients in whom plastic stents were inserted before EUS procedures. Results presented as *n* (%). AIP: Autoimmune pancreatitis; DHA: Diffuse hypoechoic area; EUS: Endoscopic ultrasound; FHA: Focal hypoechoic area; HF: Hyperechoic foci; HS: Hyperechoic strand; MPD: Main pancreatic duct; NA: Not available.

Supplement Table 4 The endoscopic ultrasound - fine-needle aspiration procedures and histopathological results of autoimmune pancreatitis patients

	Diffuse type		Focal type	
	(n = 25)		(n = 67)	
	25G Echotip	7 (28.0)	25G Echotip	16 (23.9)
	22G Echotip	14 (56.0)	22G Echotip	29 (43.3)
Needle ¹	22G Procore	2 (8.0)	22G Procore	17 (25.4)
	20G Procore	1 (4.0)	20G Procore	3 (4.5)
	19G Echotip	1 (4.0)	19G Echotip	2 (2.9)
	Slow pull	9 (36.0)	Slow pull	30 (44.8)
NT ('	5 mL suction	3 (12.0)	5 mL suction	8 (11.9)
Negative Pressure Method ²	10 mL suction	1 (4.0)	10 mL suction	1 (1.5)
	NA ²	12 (48.0)	NA	28 (41.8)
	1 pass	4 (16.0)	1 pass	14 (20.9)
Pass ³	2 passes	15 (60.0)	2 passes	44 (65.7)
	3 passes	6 (24.0)	3 passes	9 (13.4)
Core Tissue Acquisition Rate	12 (48.0)		31 (46.3)	
	LPSP Level	5 (20.0)	LPSP Level 1	15 (22.4)
Histopathological Diagnosis ⁴	LPSP Level 2	4 (16.0)	LPSP Level 2	12 (17.9)
	No evidence		No evidence	
	of	16 (64.0)	of	40 (59.7)
	malignancy		malignancy	

¹All needles used in the EUS-FNA procedures of this study were from COOK,

United States. ²As a respective study, the negative pressure method was not described in some reports of EUS-FNA procedure. ³The exact case number was given for different number of pass times. ⁴Diagnosis criteria referred to the ICDC. Results presented as n (%). AIP: Autoimmune pancreatitis; EUS: Endoscopic ultrasound; FNA: Fine-needle aspiration; ICDC: International consensus diagnostic criteria; LPSP: Lymphoplasmacytic sclerosing pancreatitis.